The agency approved Roche’s skin cancer drug Zelboraf in 2011 as a treatment for melanoma. The drug may now also be used to treat certain patients with Erdheim-Chester disease, a rare form of blood cancer. Zelboraf is the first FDA-approved treatment for this disease.
Roche’s cancer drug Alecensa earned FDA approval in 2015 to treat patients with a rare form of non-small cell lung cancer who already received prior treatment with Pfizer’s drug Xalkori. Now, Alecensa may also be used as an initial treatment for this patient population.
More articles on supply chain:
Amgen to lay off 200 research & development workers
Genentech to layoff 13% of workforce at California plant
Valeant sells $1B female libido unit back to original owners 2 years after acquisition
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.